By H. J. Bensted, W. Bulloch, L. Dudgeon, A. G. Gardner, E. D. W. Greig, D. Harvey, W. F. Harvey, T. J. Mackie, R. A. O'Brien, H. M. Perry, H. Scutze, P. Bruce White, W. J. Wilson. London, 1929. His Majesty's Stationery Office. Pp. 1–482
by A. Trevor Willis, M.D., B.S. (Melb.), Ph.D. (Leeds), M.C.Path., M.C.P.A., Reader in Microbiology, Monash University, formerly Lecturer in Bacteriology, University of Leeds. xiv + 234 pages, illustrated, second edition. Butterworth Inc., Washington. 1965. $8.50
The evaluation of sulfadiazine, sulfamethoxypyridazine (Midicel®) and sulphorthomidine (Fanzil®) alone or combined with pyrimethamine against drug-resistant strains of Plasmodium falciparum is reported. The results indicate that (1) combination of a sulfonamide with pyrimethamine enhanced the curative effect of either one alone, (2) when combined with pyrimethamine, Midicel and Fanzil were superior to sulfadiazine, and (3) of the regimens tested, 1.0 g Fanzil as a single oral dose given together with 50 mg pyrimethamine showed the most promise for the successful treatment of the multi-drug-resistant falciparum malarias. Factors limiting the usefulness of sulfonamides as antimalarials are discussed.
Cytology Section, LPC, NIAID, NIH, P. O. Box 190, Chamblee, Georgia.
Present address: Department of Pharmacology, Louisiana State University, School of Medicine, New Orleans, Louisiana.